Company Overview
Intuitive Surgical, Inc. develops, manufactures, and markets specialized products designed to enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care within the United States and internationally. The company primarily offers the da Vinci Surgical System, a technology platform that facilitates complex surgical procedures through robotic precision. Operating within the Healthcare sector, specifically in the Medical Instruments & Supplies industry, the firm leverages advanced robotics to address critical needs in modern surgical environments. The company demonstrates significant scale with a market capitalization of $170.46B and an annual revenue of $10.06B, supported by a workforce of 17,021 employees. These valuation and revenue figures indicate that Intuitive Surgical holds a substantial market position, reflecting deep capitalization and a dominant footprint in the global medical device landscape.
Financial Health
The company reported revenue of $10.06B and net income of $2.86B for the trailing twelve months, while EBITDA stood at $3.56B. The gap between revenue and net income reveals a robust cost structure where operating expenses and taxes consume approximately 71.6% of total revenue, yet the firm maintains high profitability. Free cash flow reached $2.27B, which signifies strong financial flexibility allowing the company to fund research, development, and potential acquisitions without relying on external financing. The gross margin is 66.0%, indicating that the company retains a large portion of revenue as gross profit before accounting for operating costs, a typical characteristic of high-margin medical technology firms. Operating margin is 30.2% and profit margin is 28.4%, demonstrating that the company efficiently converts a significant portion of its revenue into operating earnings and final net income. Total cash holdings of $5.93B substantially exceed total debt of $170.90M, resulting in a debt-to-equity ratio of 0.95, which suggests a conservative balance sheet with minimal leverage relative to equity. The current ratio stands at 4.88, indicating that the company possesses ample current assets to cover its short-term liabilities, highlighting exceptional short-term liquidity. Return on Equity is 16.7% and Return on Assets is 9.4%, metrics that reveal management effectiveness in generating returns for shareholders and utilizing the company's asset base efficiently.
Valuation Assessment
The trailing P/E ratio is 60.98, while the forward P/E is 41.92, implying that the market expects earnings growth that will bring the valuation multiple down from current levels over the next year. The price-to-book ratio is 9.56, indicating that the market values the company at a significant premium over its book value, reflecting expectations of superior future growth and intangible assets. The price-to-sales ratio is 16.94 and the EV/EBITDA is 46.32, suggesting that the market prices the company as a high-growth entity with substantial earnings power relative to enterprise value. The 52-week high is $603.88 and the 52-week low is $425.00, meaning the current price sits within the trading range relative to this historical volatility. The beta value is 1.68, which means the stock's price volatility is significantly higher than that of the broader market, reacting more aggressively to market movements.
Growth & Income
Revenue growth year-over-year is 18.8% and earnings growth year-over-year is 16.6%, indicating that earnings are growing slightly slower than revenue, which implies that the company is maintaining profitability despite expanding sales volumes. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all earnings into growth initiatives rather than distributing cash to shareholders. The absence of dividends combined with high free cash flow suggests a strategy focused on capital expansion and organic growth rather than income generation for current shareholders. Overall, the company presents a growth-oriented profile characterized by double-digit revenue expansion, efficient cost management, and a capital allocation strategy that prioritizes reinvestment over dividend distribution.
Peer Comparison
Intuitive Surgical, Inc. (ISRG) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:
The Medical Instruments & Supplies industry average P/E ratio is 208.0x. Intuitive Surgical, Inc. trades at a P/E of 53.2.